Navigation Links
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Date:7/18/2014

U.K. investment banking business as J.P. Morgan Cazenove and which is authorised and regulated by the Financial Conduct Authority in the United Kingdom), is acting exclusively for AbbVie in connection with the possible offer and for no one else, and is not, and will not be, responsible to anyone other than AbbVie for providing the protections afforded to clients of J.P. Morgan or its affiliates, or for providing advice in relation to the possible offer or any other matters referred to in this announcement.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the C
'/>"/>

SOURCE AbbVie Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Star Scientific and Rock Creek Pharmaceuticals Announce the Publication of a Peer-Reviewed Article about the ASAP Clinical Trial Showing Immune System Support in Hashimotos Thyroiditis
2. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the October 2013 Digital Edition Now Available Online and in the App Store
3. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
4. Labome: The Gateway to the Perfect Antibody -- Labome Antibody Review Database Has Now Reached 10,000 Peer-Reviewed Formal Publications
5. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
6. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
7. India Pharmaceutical Sector Reviewed by Kelly Scientific Publications in In-demand Report Now Available at MarketPublishers.com
8. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
9. China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
10. MarketResearch.com Announces Distribution of Kelly Scientific Publications
11. Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... BLOOMINGTON, MN (PRWEB) March 25, 2015 ... a breakthrough in nanoparticle technology that will enable ... and many other diseases with a simple breath ... ahead on the U.S. Food and Drug Administration ... 2016 launch of the innovative Nanoparticle Biomarker Tagging ...
(Date:3/25/2015)... /CNW/ - The Gairdner Foundation is pleased to ... recognizing some of the most significant medical discoveries ... the world,s most esteemed medical research prizes, the ... a $100,000 (CDN) prize to each scientist for their work. ... and innovation across the country, inspiring the next ...
(Date:3/25/2015)... 2015 Proove Biosciences , a ... to announce the success of their commercially supported symposium, ... to Optimize the Management of Pain, at the 31st ... Harbor, Maryland on Thursday, March 19th, 2015. ... President Lynn Webster , M.D., former Florida Society ...
(Date:3/25/2015)... 25, 2015 Oxis International, Inc. (OXIS) (OXI.PA) ... commercialization, announced today Oxis CEO Tony Cataldo ... 2015 at 4:15pm EST to update shareholders and other ...     Oxis Chairman and CEO Tony ... been very exciting for Oxis and our shareholders. There ...
Breaking Biology Technology:Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 42015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 52015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 62015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 72015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 8Proove Biosciences Hosts Symposium on Incorporating Genetic Testing to Optimize the Management of Pain 2Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31 2
... (OTC:,SPOM - News), a leading developer of biosensor and ... that it,has appointed Med Tech and Med Care Associates ... market. , Med Tech and ... healthcare industry and operate with manufacturers,of medical products and ...
... Md., Feb. 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 ... tolerability of Syncria (R) (albiglutide) in the long-term ... result, HGS will receive a $9 million milestone payment ...
... at the 19th Conference of the Asian Pacific ... Demonstrated Favorable Pharmacokinetics and Significant Reduction in Viral ... privately held biopharmaceutical company, today announced results from ... a controlled release version of nitazoxanide in the ...
Cached Biology Technology:SPO Medical Appoints New US Sales Rep Groups 2SPO Medical Appoints New US Sales Rep Groups 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 2Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 3Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 4
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... MOUNTAIN VIEW, Calif. , March 12, 2015 ... EDTLOCATION:Online, with Complimentary Registration here: http://bit.ly/1G7Os0L . ... Program Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... future in order to compete in several different ... the market is currently witnessing an uptrend. ...
(Date:3/10/2015)... , March 10, 2015   Tute Genomics , ... been selected by next-generation sequencing company PrimBio Research ... exome and targeted gene panel interpretation. PrimBio, ... adopted the most current technologies to support the work ... The company offers two types of exome sequencing services: ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... lacking a special protein found only in germ-line cells ... to a new study from researchers at the University ... of Human Reproduction in Penn's Center for Research in ... investigations point the way to a new type of ...
... In a recent study published in the Journal of ... to play a purely structural and inert role in ... Using antagonists for this molecule, the researchers were able ... drug treatment. , The research appears as the "Paper ...
... of neuroscientists have been indoctrinated into believing that ... by a communication network of brain cells, or ... message called a neurotransmitter. Either neurons release a ... an electrical discharge and enhancing brain activity, or ...
Cached Biology News:Of mice and men's (and women's) contraceptives 2New polysaccharide may help combat multidrug resistance in cancer 2Researchers make surprise discovery that some neurons can transmit three signals at once 2Researchers make surprise discovery that some neurons can transmit three signals at once 3
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... gap filling, localized cloning of genomic DNA, ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Biology Products: